Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.55 |
| ▸ | BRAF | P15056 | 18/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL914339 | 0.83 | BRAF (0.75) | BRAF | |
| SCHEMBL287869 | 0.83 | ABL1 (0.57) | ABL1BRAFCYP3A4CYP2C19 | |
| SCHEMBL24037814 | 0.79 | BRAF (0.47) | BRAF | |
| SCHEMBL3029616 | 0.77 | BRAF (0.66) | BRAFCYP3A4CYP2C19 | |
| SCHEMBL299416 | 0.77 | ABL1 (0.57) | ABL1BRAFCYP3A4CYP2C19 | |
| SCHEMBL21151427 | 0.77 | BRAF (0.44) | BRAF | |
| SCHEMBL3019900 | 0.76 | ABL1 (0.58) | ABL1BRAFCYP3A4CYP2C19 | |
| SCHEMBL24001473 | 0.74 | ABL1 (0.47) | ABL1BRAFCYP3A4CYP2C19 | |
| SCHEMBL21086751 | 0.74 | BRAF (0.50) | BRAF | |
| SCHEMBL3025701 | 0.73 | BRAF (0.65) | BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210353602-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2021-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210353602-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | ABL1 113/4885BRAF 48/4885CYP3A4 4658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.